{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T06:46:53Z","timestamp":1793774813635,"version":"4.6.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100022963","name":"Key R&D Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2023C03009"],"award-info":[{"award-number":["2023C03009"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100022963","name":"Key R&D Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2023C03022"],"award-info":[{"award-number":["2023C03022"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370026"],"award-info":[{"award-number":["82370026"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82225001"],"award-info":[{"award-number":["82225001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Fundamental Research Funds for the Central Universities","award":["226-2024-00175"],"award-info":[{"award-number":["226-2024-00175"]}]},{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2021YFA1102001"],"award-info":[{"award-number":["2021YFA1102001"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clonal and pathogenic eosinophil expansion in hypereosinophilic disorders (e.g., refractory hypereosinophilic syndrome (HES) and chronic eosinophilic leukemia (CEL)) remains an unmet therapeutic challenge, with current strategies often failing to induce durable remission. While monoclonal antibodies targeting the IL-5\/IL-5R\u03b1 pathway have shown efficacy in treating eosinophil-driven diseases, a subset of patients experience incomplete responses or relapses, highlighting the need for more durable and comprehensive therapeutic strategies. Chimeric antigen receptor T (CAR-T) cell therapy, with its potential for long-term persistence and durable remission after a single infusion, represents a promising alternative for patients with refractory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed single-cell RNA sequencing on peripheral blood (PB) and bone marrow (BM) samples from both healthy individuals and the patient with hypereosinophilic disorder, to identify key therapeutic targets for intervention. Based on these findings, we developed a first-in-class CAR-T therapy using human interleukin-5 (hIL-5) as a ligand-based targeting domain, to selectively recognize and eliminate IL-5R\u03b1\n                      <jats:sup>+<\/jats:sup>\n                      eosinophils and precursors. In vitro cytotoxicity  and IFN-\u03b3 secretion were measured against target cells and patient-derived PB\/BM samples. Preclinical safety was evaluated through comprehensive toxicity assessment. Efficacy was evaluated in a hypereosinophilic leukemia mouse model, with tumor burden reduction and survival as the key evaluation indicators.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Single-cell profiling revealed concurrent expansion of both eosinophil progenitors and mature eosinophils in the BM and PB, highlighting the need for therapies targeting all stages of eosinophil development. IL-5 receptor \u03b1 (IL-5R\u03b1) was identified as the optimal target due to its high expression across all stages of eosinophil development, with relatively restricted expression on non-eosinophil immune populations. hIL-5 CAR-T cells demonstrated potent in vitro cytotoxicity and IFN-\u03b3 secretion against target cells and effectively eliminated eosinophils in patient-derived PB\/BM samples. No dose-limiting toxicities were observed, and no evidence of cytokine release syndrome (CRS) was detected in preclinical models. In the hypereosinophilic leukemia mouse model, a single infusion of hIL-5 CAR-T cells significantly reduced tumor burden and extended survival, demonstrating its therapeutic potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>IL-5 CAR-T cell therapy represents a promising targeted therapeutic approach for IL-5R\u03b1-expressing hypereosinophilic disorders. Its ability to target eosinophils and their precursors across all developmental stages in BM and PB addresses a critical unmet medical need in refractory HES and CEL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-026-01782-x","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:34:53Z","timestamp":1770996893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders"],"prefix":"10.1186","volume":"19","author":[{"given":"Youqian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingpeng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoyu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehua","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongrui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songmin","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"issue":"6","key":"1782_CR1","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJM200002103420619","volume":"342","author":"JL Leone","year":"2000","unstructured":"Leone JL. Hypereosinophilic syndrome. N Engl J Med. 2000;342(6):442.","journal-title":"N Engl J Med"},{"issue":"13","key":"1782_CR2","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMp030019","volume":"348","author":"RS Schwartz","year":"2003","unstructured":"Schwartz RS. The hypereosinophilic syndrome and the biology of cancer. N Engl J Med. 2003;348(13):1199\u2013200.","journal-title":"N Engl J Med"},{"issue":"14","key":"1782_CR3","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood.2020010648","volume":"137","author":"Y Sandberg","year":"2021","unstructured":"Sandberg Y, Weerkamp F. Charcot-leyden crystals in chronic eosinophilic leukemia. Blood. 2021;137(14):1985.","journal-title":"Blood"},{"issue":"3","key":"1782_CR4","first-page":"171","volume":"59","author":"AM Vannucchi","year":"2009","unstructured":"Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171\u201391.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1782_CR5","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1038\/bcj.2014.95","volume":"5","author":"ZR Chalmers","year":"2015","unstructured":"Chalmers ZR, Ali SM, Ohgami RS, Campregher PV, Frampton GM, Yelensky R, et al. Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to Imatinib therapy. Blood Cancer J. 2015;5(2):e278.","journal-title":"Blood Cancer J"},{"issue":"5","key":"1782_CR6","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/ajh.27287","volume":"99","author":"W Shomali","year":"2024","unstructured":"Shomali W, Gotlib J. World health organization and international consensus classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management. Am J Hematol. 2024;99(5):946\u201368.","journal-title":"Am J Hematol"},{"issue":"1","key":"1782_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg OS, Spagnuolo L, Garner H, Voorwerk L, Isaeva OI, van Dyk E, et al. IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint Blockade in breast cancer. Cancer Cell. 2023;41(1):106\u2013e12310.","journal-title":"Cancer Cell"},{"issue":"7","key":"1782_CR8","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/j.immuni.2024.04.027","volume":"57","author":"J Jorssen","year":"2024","unstructured":"Jorssen J, Van Hulst G, Mollers K, Pujol J, Petrellis G, Baptista AP, et al. Single-cell proteomics and transcriptomics capture eosinophil development and identify the role of IL-5 in their lineage transit amplification. Immunity. 2024;57(7):1549\u201366. e8.","journal-title":"Immunity"},{"issue":"10","key":"1782_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler ME, Nair P, Terrier B, Walz B, Bourdin A, Jayne DRW, et al. Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2024;390(10):911\u201321.","journal-title":"N Engl J Med"},{"issue":"3","key":"1782_CR10","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s10875-020-00946-9","volume":"41","author":"I Alen Coutinho","year":"2021","unstructured":"Alen Coutinho I, Regateiro FS, Loureiro C, Todo-Bom A. Benralizumab in severe and refractory PDGFRA-negative hypereosinophilic syndrome. J Clin Immunol. 2021;41(3):688\u201390.","journal-title":"J Clin Immunol"},{"issue":"12","key":"1782_CR11","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1056\/NEJMoa070812","volume":"358","author":"ME Rothenberg","year":"2008","unstructured":"Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215\u201328.","journal-title":"N Engl J Med"},{"issue":"14","key":"1782_CR12","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1056\/NEJMoa1812185","volume":"380","author":"FL Kuang","year":"2019","unstructured":"Kuang FL, Legrand F, Makiya M, Ware J, Wetzler L, Brown T, et al. Benralizumab for PDGFRA-negative hypereosinophilic syndrome. N Engl J Med. 2019;380(14):1336\u201346.","journal-title":"N Engl J Med"},{"issue":"5","key":"1782_CR13","first-page":"1518","volume":"6","author":"FL Kuang","year":"2018","unstructured":"Kuang FL, Fay MP, Ware J, Wetzler L, Holland-Thomas N, Brown T, et al. Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome. The Journal of Allergy and Clinical Immunology: In Practice. 2018;6(5):1518-1527 e5.","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice"},{"issue":"2","key":"1782_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.pccm.2025.05.001","volume":"3","author":"S Thawanaphong","year":"2025","unstructured":"Thawanaphong S, Nolasco S, Nair P. Achieving remission in severe asthma. Chin Med J Pulm Crit Care Med. 2025;3(2):77\u201387.","journal-title":"Chin Med J Pulm Crit Care Med"},{"issue":"12","key":"1782_CR15","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","volume":"9","author":"GJ Gleich","year":"2021","unstructured":"Gleich GJ, Roufosse F, Chupp G, Faguer S, Walz B, Reiter A, et al. Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study. J Allergy Clin Immunol Pract. 2021;9(12):4431-4440 e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"1782_CR16","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","volume":"146","author":"F Roufosse","year":"2020","unstructured":"Roufosse F, Kahn JE, Rothenberg ME, Wardlaw AJ, Klion AD, Kirby SY, et al. Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a phase III, randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;146(6):1397\u2013405.","journal-title":"J Allergy Clin Immunol"},{"issue":"14","key":"1782_CR17","first-page":"1632","volume":"136","author":"C Tong","year":"2020","unstructured":"Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19\/CD20 CAR-engineered T cells in refractory\/relapsed B-cell lymphoma. Blood. 2020;136(14):1632\u201344.","journal-title":"Blood"},{"issue":"7926","key":"1782_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","volume":"609","author":"J Zhang","year":"2022","unstructured":"Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022;609(7926):369\u201374.","journal-title":"Nature"},{"issue":"2","key":"1782_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","volume":"30","author":"BL Levine","year":"2024","unstructured":"Levine BL, Pasquini MC, Connolly JE, Porter DL, Gustafson MP, Boelens JJ, et al. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy. Nat Med. 2024;30(2):338\u201341.","journal-title":"Nat Med"},{"key":"1782_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258367","author":"HC Fan","year":"2015","unstructured":"Fan HC, Fu GK, Fodor SPA. Combinatorial labeling of single cells for gene expression cytometry. Science. 2015. https:\/\/doi.org\/10.1126\/science.1258367.","journal-title":"Science"},{"key":"1782_CR21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.124928","author":"KA Oetjen","year":"2018","unstructured":"Oetjen KA, Lindblad KE, Goswami M, Gui G, Dagur PK, Lai C, et al. Human bone marrow assessment by single-cell RNA sequencing, mass cytometry, and flow cytometry. JCI Insight. 2018. https:\/\/doi.org\/10.1172\/jci.insight.124928.","journal-title":"JCI Insight"},{"issue":"7","key":"1782_CR22","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive integration of single-cell data. Cell. 2019;177(7):1888-1902.e21.","journal-title":"Cell"},{"issue":"4","key":"1782_CR23","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cels.2018.11.005","volume":"8","author":"SL Wolock","year":"2019","unstructured":"Wolock SL, Lopez R, Klein AM. Scrublet: computational identification of cell doublets in single-cell transcriptomic data. Cell Syst. 2019;8(4):281-291.e9.","journal-title":"Cell Syst"},{"issue":"6","key":"1782_CR24","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/10408363.2019.1633512","volume":"56","author":"M Poorebrahim","year":"2019","unstructured":"Poorebrahim M, Sadeghi S, Fakhr E, Abazari MF, Poortahmasebi V, Kheirollahi A, et al. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects. Crit Rev Clin Lab Sci. 2019;56(6):393\u2013419.","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"1","key":"1782_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med. 2019;25(1):82\u20138.","journal-title":"Nat Med"},{"issue":"7814","key":"1782_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127\u201332.","journal-title":"Nature"},{"issue":"9","key":"1782_CR27","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/s41591-019-0549-5","volume":"25","author":"S Ghorashian","year":"2019","unstructured":"Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al. Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med. 2019;25(9):1408\u201314.","journal-title":"Nat Med"},{"key":"1782_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1919","volume":"3","author":"J Huang","year":"2012","unstructured":"Huang J, Yan J, Zhang J, Zhu S, Wang Y, Shi T, et al. SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun. 2012;3:911.","journal-title":"Nat Commun"},{"key":"1782_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1435934","volume":"15","author":"J Guo","year":"2024","unstructured":"Guo J, Wu Q, Li H, Liang C, Dai J, Zhang S, et al. Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma. Front Immunol. 2024;15:1435934.","journal-title":"Front Immunol"},{"issue":"1","key":"1782_CR30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","volume":"36","author":"X Si","year":"2024","unstructured":"Si X, Shao M, Teng X, Huang Y, Meng Y, Wu L, et al. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell Metab. 2024;36(1):176-192 e10.","journal-title":"Cell Metab"},{"issue":"8","key":"1782_CR31","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","volume":"103","author":"AD Klion","year":"2004","unstructured":"Klion AD, Law MA, Noel P, Kim YJ, Haverty TP, Nutman TB. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome. Blood. 2004;103(8):2939\u201341.","journal-title":"Blood"},{"issue":"4","key":"1782_CR32","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","volume":"126","author":"F Roufosse","year":"2010","unstructured":"Roufosse F, de Lavareille A, Schandene L, Cogan E, Georgelas A, Wagner L, et al. Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol. 2010;126(4):828-835 e3.","journal-title":"J Allergy Clin Immunol"},{"issue":"7971","key":"1782_CR33","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315.","journal-title":"Nature"},{"issue":"1","key":"1782_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-022-00433-y","volume":"8","author":"S Chen","year":"2022","unstructured":"Chen S, Chen G, Xu F, Sun B, Chen X, Hu W, et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. Cell Discov. 2022;8(1):80.","journal-title":"Cell Discov"},{"issue":"6","key":"1782_CR35","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/s41590-024-01834-9","volume":"25","author":"G Jin","year":"2024","unstructured":"Jin G, Liu Y, Wang L, He Z, Zhao X, Ma Y, et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. Nat Immunol. 2024;25(6):1059\u201372.","journal-title":"Nat Immunol"},{"issue":"6","key":"1782_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/j.jaci.2023.03.011","volume":"151","author":"ME Wechsler","year":"2023","unstructured":"Wechsler ME, Hellmich B, Cid MC, Jayne D, Tian X, Baylis L, et al. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol. 2023;151(6):1415\u201328.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1782_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nbt.4086","volume":"36","author":"K Adachi","year":"2018","unstructured":"Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol. 2018;36(4):346\u201351.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"1782_CR38","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41591-022-01916-x","volume":"28","author":"N Scholler","year":"2022","unstructured":"Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, et al. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma. Nat Med. 2022;28(9):1872\u201382.","journal-title":"Nat Med"},{"issue":"2","key":"1782_CR39","doi-asserted-by":"publisher","first-page":"e20192203","DOI":"10.1084\/jem.20192203","volume":"218","author":"E Lanitis","year":"2021","unstructured":"Lanitis E, Rota G, Kosti P, Ronet C, Spill A, Seijo B, et al. Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression. J Exp Med. 2021;218(2):e20192203.","journal-title":"J Exp Med"},{"issue":"3","key":"1782_CR40","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","volume":"8","author":"SA Batra","year":"2020","unstructured":"Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, et al. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res. 2020;8(3):309\u201320.","journal-title":"Cancer Immunol Res"},{"issue":"10","key":"1782_CR41","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1158\/2159-8290.CD-21-1026","volume":"12","author":"YG Lee","year":"2022","unstructured":"Lee YG, Guruprasad P, Ghilardi G, Pajarillo R, Sauter CT, Patel R, et al. Modulation of BCL-2 in both T cells and tumor cells to enhance chimeric antigen receptor T-cell immunotherapy against cancer. Cancer Discov. 2022;12(10):2372\u201391.","journal-title":"Cancer Discov"},{"issue":"2","key":"1782_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","volume":"39","author":"S Srivastava","year":"2021","unstructured":"Srivastava S, Furlan SN, Jaeger-Ruckstuhl CA, Sarvothama M, Berger C, Smythe KS, et al. Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade. Cancer Cell. 2021;39(2):193-208 e10.","journal-title":"Cancer Cell"},{"issue":"5","key":"1782_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, Adusumilli PS. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer Cell. 2019;36(5):471\u201382.","journal-title":"Cancer Cell"},{"issue":"9","key":"1782_CR44","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41590-023-01571-5","volume":"24","author":"X Zhou","year":"2023","unstructured":"Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, et al. CTLA-4 tail fusion enhances CAR-T antitumor immunity. Nat Immunol. 2023;24(9):1499\u2013510.","journal-title":"Nat Immunol"},{"issue":"10","key":"1782_CR45","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","volume":"56","author":"S Agarwal","year":"2023","unstructured":"Agarwal S, Aznar MA, Rech AJ, Good CR, Kuramitsu S, Da T, et al. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells. Immunity. 2023;56(10):2388\u2013407. e9.","journal-title":"Immunity"},{"issue":"3","key":"1782_CR46","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-21-0694","volume":"12","author":"F Wiede","year":"2022","unstructured":"Wiede F, Lu KH, Du X, Zeissig MN, Xu R, Goh PK, et al. PTP1B is an intracellular checkpoint that limits T-cell and CAR T-cell antitumor immunity. Cancer Discov. 2022;12(3):752\u201373.","journal-title":"Cancer Discov"},{"issue":"722","key":"1782_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adg6752","volume":"15","author":"S Ma","year":"2023","unstructured":"Ma S, Tian Y, Peng J, Chen C, Peng X, Zhao F, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023;15(722):eadg6752.","journal-title":"Sci Transl Med"},{"issue":"4","key":"1782_CR48","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724\u201334.","journal-title":"Nat Med"},{"issue":"13","key":"1782_CR49","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1158\/0008-5472.CAN-23-2874","volume":"84","author":"X Xu","year":"2024","unstructured":"Xu X, Zhang Y, Lu Y, Zhang X, Zhao C, Wang J, et al. CD58 alterations govern antitumor immune responses by inducing PDL1 and IDO in diffuse large B-cell lymphoma. Cancer Res. 2024;84(13):2123\u201340.","journal-title":"Cancer Res"},{"issue":"25","key":"1782_CR50","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","volume":"125","author":"S Ninomiya","year":"2015","unstructured":"Ninomiya S, Narala N, Huye L, Yagyu S, Savoldo B, Dotti G, et al. Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. Blood. 2015;125(25):3905\u201316.","journal-title":"Blood"},{"issue":"11","key":"1782_CR51","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/j.ccell.2022.08.008","volume":"40","author":"HS Li","year":"2022","unstructured":"Li HS, Wong NM, Tague E, Ngo JT, Khalil AS, Wong WW. High-performance multiplex drug-gated CAR circuits. Cancer Cell. 2022;40(11):1294\u2013305. e4.","journal-title":"Cancer Cell"},{"issue":"10","key":"1782_CR52","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh L, Majzner RG, Klysz D, Sotillo E, Fisher CJ, Vilches-Moure JG, et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell. 2022;185(10):1745\u201363. e22.","journal-title":"Cell"},{"issue":"10","key":"1782_CR53","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","volume":"24","author":"M Ruella","year":"2018","unstructured":"Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018;24(10):1499\u2013503.","journal-title":"Nat Med"},{"issue":"6","key":"1782_CR54","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/j.1398-9995.2004.00476.x","volume":"59","author":"D Simon","year":"2004","unstructured":"Simon D, Braathen LR, Simon HU. Eosinophils and atopic dermatitis. Allergy. 2004;59(6):561\u201370.","journal-title":"Allergy"},{"issue":"5","key":"1782_CR55","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/gut.2008.165894","volume":"58","author":"BM Yan","year":"2009","unstructured":"Yan BM, Shaffer EA. Primary eosinophilic disorders of the gastrointestinal tract. Gut. 2009;58(5):721\u201332.","journal-title":"Gut"},{"issue":"6","key":"1782_CR56","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi G, Bettiol A, Gelain E, Bajema IM, Berti A, Burns S, et al. Evidence-Based guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nat Rev Rheumatol. 2023;19(6):378\u201393.","journal-title":"Nat Rev Rheumatol"},{"key":"1782_CR57","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1146\/annurev-pathmechdis-012419-032756","volume":"15","author":"AD Klion","year":"2020","unstructured":"Klion AD, Ackerman SJ, Bochner BS. Contributions of eosinophils to human health and disease. Annu Rev Pathol. 2020;15:179\u2013209.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"1782_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41572-025-00595-5","volume":"11","author":"H Akbarialiabad","year":"2025","unstructured":"Akbarialiabad H, Schmidt E, Patsatsi A, Lim YL, Mosam A, Tasanen K, et al. Bullous pemphigoid. Nat Rev Dis Primers. 2025;11(1):12.","journal-title":"Nat Rev Dis Primers"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-026-01782-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01782-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-026-01782-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T12:04:33Z","timestamp":1784117073000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-026-01782-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1782"],"URL":"https:\/\/doi.org\/10.1186\/s13045-026-01782-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.M.Y is an inventor of the Chinese patent ZL 2021 1 0172889.1 (granted, titled \u201cChimeric Antigen Receptor with Endogenous Protein Molecule Replacing Single Domain Antibody\u201d) and the corresponding international patent application WO 2022\/166665 A1 filed by ZJU.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"18"}}